LightDark Log in Sign up

‹ Back to screener

SYNGENE.NS Syngene International Ltd.

Healthcare

Price history

2025-08-21 ₹667.80
2026-08-21 ₹407.65
Change over window -38.96%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 57.8%
Trailing 20-day average 54.9%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 293096 169258 57.75%
2026-08-27 479502 252566 52.67%
2026-08-26 567950 242749 42.74%
2026-08-25 399141 208706 52.29%
2026-08-24 268563 144956 53.97%
2026-08-21 953583 475631 49.88%
2026-08-20 1883583 1173819 62.32%
2026-08-19 366481 167660 45.75%
2026-08-18 335081 203435 60.71%
2026-08-17 306199 200045 65.33%
2026-08-14 497308 295773 59.47%
2026-08-13 810276 448761 55.38%
2026-08-12 591399 378298 63.97%
2026-08-11 405459 218934 54.00%
2026-08-10 1885130 1227435 65.11%
2026-08-07 2260564 1438180 63.62%
2026-08-06 806023 352554 43.74%
2026-08-05 541762 276606 51.06%
2026-08-04 925377 442678 47.84%
2026-08-03 1674593 857211 51.19%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers SYNGENE.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
27 Dec 2024 ANJAN CHAKRABARTI Employees/Designated Employees Sell Market Sale 6190 5265152 0.01% XBRL
23 Dec 2024 ANJAN CHAKRABARTI Employees/Designated Employees Buy ESOP 58390 50199635 0.01% XBRL
23 Dec 2024 ANJAN CHAKRABARTI Employees/Designated Employees Sell Market Sale 27200 22944288 0.01% XBRL
11 Dec 2024 Biocon Limited Promoters Sell Market Sale 8000000 6861440000 52.46% XBRL
28 Nov 2024 DEEPAK VENKATRAMAN Employees/Designated Employees Sell Market Sale 600 533610 0.00% XBRL
28 Nov 2024 DEEPAK VENKATRAMAN Employees/Designated Employees Sell Market Sale 600 544290 0.00% XBRL
28 Nov 2024 Mayank Verma Employees/Designated Employees Sell Market Sale 1500 1369755 0.00% XBRL
18 Nov 2024 ALOK MEHROTRA Employees/Designated Employees Buy ESOP 20000 17520600 0.01% XBRL
18 Nov 2024 ALOK MEHROTRA Employees/Designated Employees Sell Market Sale 8200 7037404 0.01% XBRL
11 Nov 2024 SIBAJI BISWAS Key Managerial Personnel Buy ESOP 86431 76917540 0.04% XBRL
11 Nov 2024 SIBAJI BISWAS Key Managerial Personnel Sell Market Sale 35000 31977400 0.03% XBRL
05 Sep 2024 CHETAN PRAKASH TAMHANKA Employees/Designated Employees Sell Market Sale 2394 2091398 0.01% XBRL
04 Sep 2024 Ajit Manocha Employees/Designated Employees Sell Market Sale 2587 2276560 0.00% XBRL
03 Sep 2024 Ajit Manocha Employees/Designated Employees Sell Market Sale 2500 2180000 0.00% XBRL
29 Aug 2024 Ajit Manocha Employees/Designated Employees Sell Market Sale 5000 4225000 0.00% XBRL
28 Aug 2024 ALOK MEHROTRA Employees/Designated Employees Sell Market Sale 1000 853990 0.01% XBRL
28 Aug 2024 ALOK MEHROTRA Employees/Designated Employees Sell Market Sale 500 428540 0.01% XBRL
27 Aug 2024 G KRISHNAN Employees/Designated Employees Sell Market Sale 5000 4234400 0.00% XBRL
27 Aug 2024 Manoj Gupta Employees/Designated Employees Sell Market Sale 6400 5443200 0.00% XBRL
23 Aug 2024 CHETAN PRAKASH TAMHANKA Employees/Designated Employees Buy ESOP 17287 14386241 0.01% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers SYNGENE.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹407.25 INR (live) · fetched 2026-08-24 00:31 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Ratios

P/E
51.81
P/E = Price / EPS
P/E (Price to Earnings)

What the market pays today for one rupee of last year's profit.

P/E = Price ÷ (Net Income ÷ Diluted Shares Outstanding)

P/E divides the share price by earnings per share. If a share costs ₹300 and the company earned ₹15 per share, the P/E is 20 — buyers are paying twenty rupees for each rupee of annual profit.

A high P/E is not automatically 'expensive' and a low one is not automatically 'cheap'. A high number can mean the market expects profits to grow, or that the last year's profit was unusually low. A low number can mean the market expects profits to fall. P/E on its own says nothing about whether a price is justified — it is a starting question, not an answer.

P/E is undefined when a company made a loss, because dividing by a negative or zero profit produces a figure that cannot be read the normal way. StockProof shows N/A rather than a negative P/E.

In StockProof StockProof computes this from the latest cached price and the net income and diluted share count in the most recent filing on file. The historical P/E chart uses a different basis — filed annual EPS against an adjusted closing price — so the two figures are not directly comparable and are never differenced.

Introduction to the price-to-earnings ratio ↗ Khan Academy — external link, not StockProof content

Source trace
P/E = Price / (ProfitLossForPeriod / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹407.25 / (₹3,167,000,000 / 402,900,000 shares) = ₹407.25 / ₹7.86 EPS
FY2025-26 · Annual filing
ROE
6.54%
ROE = Net Income / Shareholder Equity
ROE (Return on Equity)

How much profit the company generated per rupee of shareholders' own money.

ROE = Net Income ÷ Shareholder Equity

ROE divides net income by shareholders' equity — the money owners have put in plus the profits kept in the business rather than paid out. An ROE of 18% means the business turned every ₹100 of owners' capital into ₹18 of annual profit.

ROE is flattered by debt. A company that funds itself heavily with borrowing has less equity in the denominator, so the same profit produces a higher ROE. Two companies with identical ROE can carry completely different risk, which is why ROE is read next to Debt/Equity rather than on its own — and why the DuPont decomposition below exists.

In StockProof Equity here is the figure filed in the most recent annual or quarterly statement. For banks and NBFCs the composite differs from a manufacturer's, which is why the source-trace line under each figure names the exact filed line item used.

DuPont decomposition

Splits ROE into three parts, so you can see whether it came from margin, efficiency, or debt.

ROE = (Net Income ÷ Revenue) × (Revenue ÷ Total Assets) × (Total Assets ÷ Equity)

The same ROE can be produced three very different ways. DuPont breaks it into Net Profit Margin × Asset Turnover × Equity Multiplier — how much profit each rupee of sales leaves, how much sales each rupee of assets generates, and how many rupees of assets sit on each rupee of equity.

A luxury brand reaches its ROE through margin. A supermarket reaches a similar ROE through turnover on thin margins. A leveraged lender reaches it through the equity multiplier. Only the third of those raises ROE by raising risk, and a single ROE number cannot tell you which of the three you are looking at.

This is why a rise in ROE is worth taking apart before it is treated as good news: an ROE that improved because the company borrowed more is a different fact from an ROE that improved because margins widened.

In StockProof StockProof does not yet render the three-way split as its own view — it is on the roadmap. The explanation is here because it is the right way to read the ROE figure shown beside it.

Source trace
ROE = ProfitLossForPeriod / EquityAttributableToOwnersOfParent → ₹3,167,000,000 / ₹48,391,000,000 = 6.54%
FY2025-26 · Annual filing
Debt/Equity
0.00
Debt/Equity = Total Debt / Shareholder Equity
Debt / Equity

How many rupees the company has borrowed for each rupee of owners' money.

Debt / Equity = Total Debt ÷ Shareholder Equity

A Debt/Equity of 0.5 means fifty paise of borrowing per rupee of equity; a figure of 2.0 means two rupees of borrowing per rupee of equity. It is the plainest single measure of how much of the business is funded by lenders rather than owners.

Borrowing is not itself a fault. It magnifies outcomes in both directions: the same leverage that lifts returns in a good year deepens losses in a bad one, and interest has to be paid whether or not the year was good. What counts as a lot depends entirely on the industry — a utility with contracted cash flows and a cyclical commodity producer are not comparable on this number.

Financial companies are the clearest case: for a bank or an NBFC, borrowing IS the raw material of the business, so a Debt/Equity that would be alarming for a manufacturer is ordinary for a lender.

In StockProof Both figures come from the same filing, so the ratio is internally consistent even when the filing itself is restated later.

Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹94,000,000 / ₹48,391,000,000 = 0.00
FY2025-26 · Annual filing
Current Ratio
1.38
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹21,428,000,000 / ₹15,523,000,000 = 1.38
FY2025-26 · Annual filing
ROCE
11.06%
ROCE = EBIT / (Shareholder Equity + Total Debt)
ROCE (Return on Capital Employed)

Return on ALL the long-term money in the business, borrowed as well as owned.

ROCE = EBIT ÷ (Total Equity + Total Debt)

ROCE divides operating profit (EBIT) by capital employed — equity plus debt. Where ROE asks what the owners earned, ROCE asks what the whole business earned on every rupee financed into it, whoever supplied that rupee.

Because the denominator includes debt, ROCE is not flattered by borrowing the way ROE is. That makes it the more comparable figure across companies with different capital structures, and the usual first check on whether a business is genuinely productive or merely leveraged.

A useful reference point is the company's own cost of borrowing: a business earning a ROCE below what it pays on its debt is consuming value on each additional rupee it employs.

In StockProof For lenders (banks, NBFCs, housing finance companies) the balance sheet has no current/non-current split and Finance Costs are close to a core operating cost rather than a financing item. StockProof still shows ROCE for those filers but prints an explicit caveat beside it — that caveat is not part of Learning Mode and shows whether or not this mode is on.

Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹5,363,000,000 / (₹48,391,000,000 + ₹94,000,000) = 11.06%
FY2025-26 · Annual filing
Dividend Yield
0.31%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹504,000,000 / 402,900,000 shares) / ₹407.25 = ₹1.25 / ₹407.25
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 5.4%
Net Profit (3y) N/A
Revenue (5y, 3.0y actual) 5.4%
Net Profit (5y) N/A
Revenue (10y, 3.0y actual) 5.4%
Net Profit (10y) N/A

Operating Margin Trend

Eroding

FY2022-23 20.0%
FY2023-24 19.5%
FY2024-25 18.7%
FY2025-26 14.3%

ROCE Trajectory

FY2022-23 15.2%
FY2023-24 15.4%
FY2024-25 14.1%
FY2025-26 11.1%

Earnings Quality

Net profit or operating cash flow was zero or negative in the base or latest year — a growth-rate comparison isn't defined across a sign change.

Sector-Relative Percentile (Healthcare)

ROE 15th
ROCE 15th
Debt/Equity 76th
P/E 48th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹916.90 Cr. ₹789.70 Cr. ₹891.00 Cr. ₹943.70 Cr. ₹1,018.00 Cr. ₹874.50 Cr. ₹910.60 Cr. ₹917.10 Cr. ₹1,036.50 Cr. ₹736.00 Cr. RevenueFromOperations
Net Profit ₹188.60 Cr. ₹75.70 Cr. ₹106.10 Cr. ₹131.10 Cr. ₹183.30 Cr. ₹86.70 Cr. ₹67.10 Cr. ₹15.00 Cr. ₹147.90 Cr. ₹-9.00 Cr. ProfitLossForPeriod

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers SYNGENE.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitLossForPeriod3167000000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital402900000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets21428000000.0
CurrentLiabilities15523000000.0
EquityAttributableToOwnersOfParent48391000000.0
BorrowingsCurrent + BorrowingsNoncurrent94000000.0

My notes